 | |
| Clinical data | |
|---|---|
| Trade names | Vonedrine |
| Other names | N,β-Dimethylphenethylamine; β,N-Dimethylphenethylamine;N,β-Dimethylbenzeneethanamine; Phenylpropylmethylamine;N-Methyl-2-phenylpropan-1-amine; MPPA; BMMPEA; β-Me-NMPEA; β,N-MePEA |
| Routes of administration | Nasal inhaler |
| Drug class | Norepinephrine–dopamine releasing agent |
| ATC code |
|
| Legal status | |
| Legal status | |
| Identifiers | |
| |
| CAS Number | |
| PubChemCID | |
| ChemSpider | |
| UNII | |
| CompTox Dashboard(EPA) | |
| ECHA InfoCard | 100.257.912 |
| Chemical and physical data | |
| Formula | C10H15N |
| Molar mass | 149.237 g·mol−1 |
| 3D model (JSmol) | |
| |
| |
| (verify) | |
Phenpromethamine (former brand nameVonedrine), also known asN,β-dimethylphenethylamine (MPPA,BMMPEA,β-Me-NMPEA,β,N-MePEA), is asympathomimeticnasal decongestant of thephenethylamine group.[1][2][3][4] It was previously marketed as anasal inhaler from 1943 through 1960 but is no longer available.[4][3][5] The medication is astimulant and is banned by theWorld Anti-Doping Agency.[6][3] It has been detected indietary supplements starting in the 2010s.[5][4]
The drug is amonoamine releasing agent (MRA) similarly toβ-phenethylamine,amphetamine, and other phenethylamines.[7] It is theN-methylderivative ofβ-methylphenethylamine (BMPEA) and the β-methyl derivative ofN-methylphenethylamine (NMPEA).[7] Phenpromethamine is known to act as anorepinephrine–dopamine releasing agent (NDRA), withEC50Tooltip half-maximal effective concentration values of 154 nM fornorepinephrine and 574 nM fordopamine in rat brainsynaptosomes, whereasserotonin was not reported.[7]
 | Thispsychoactive drug-related article is astub. You can help Wikipedia byexpanding it. |